FDA sets deadline to end sales of Ozempic, Wegovy copycats
Semaglutide — the key ingredient in Ozempic and Wegovy — had been in shortage since 2022. Now that supply has stabilized, state-licensed compounding pharmacies and physicians must stop selling compounded semaglutide by April 22, while outsourcing facilities have until May 22 to cease production and distribution.
Hims & Hers is stopping its sales of an alternative to blockbuster weight-loss drugs Wegovy and Ozempic. That follows the U.S ...
People who have depended on off-brand versions of Wegovy and Ozempic will likely have to pay more now that a nationwide ...
The Trump administration, perhaps surprisingly, chose to defend the legality of the Inflation Reduction Act’s (IRA’s) drug ...
Some workers are willing to trade vacation days or go back to the office in exchange for weight-loss drug coverage by their ...
Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...
If the CMS rule to cover obesity medications is finalized, coverage will increase by other insurers, experts predicted. HHS ...
The Biden administration has proposed a new rule to “significantly” expand coverage of anti-obesity medications for Americans with Medicare and Medicaid ... the active ingredient found in Ozempic ...
Medicare is undergoing sweeping changes in 2025, including a $2,000 limit on out-of-pocket Part D drug costs, the elimination ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback